Eckert & Ziegler SE (FRA:EUZ)

Market Cap	824.76M -24.5%
Revenue (ttm)	312.50M +4.4%
Net Income	49.74M +35.7%
EPS	0.79 +36.4%
Shares Out	n/a
PE Ratio	16.58
Forward PE	15.80
Dividend	0.22 (1.66%)
Ex-Dividend Date	Jun 25, 2026

Volume	n/a
Open	13.16
Previous Close	13.29
Day's Range	13.16 - 13.16
52-Week Range	13.16 - 18.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 1,105
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EUZ

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 26, 2026

Data Sources Report a data error